A Phase 1b/2 Study of Palazestrant (OP-1250) in Combination With Ribociclib in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2−), Advanced and/or Metastatic Breast Cancer
Poster: 2024 San Antonio Breast Cancer Symposium. #P2-09-16
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs. standard-of-care treatment for ER+/HER2− advanced or metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy
Poster: 2024 American Society of Clinical Oncologists (ASCO) Annual Meeting. #105b
A phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced and/or metastatic breast cancer
Poster: 2024 ESMO Breast Cancer Annual Congress, #212P
Palazestrant (OP-1250), a complete estrogen receptor antagonist, inhibits wild-type and mutant ER-positive breast cancer models as monotherapy and in combination
Molecular Cancer Therapeutics 2024 Mar 4;23(3): 285-300
A phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced and/or metastatic breast cancer
Poster: 2023 San Antonio Breast Cancer Symposium. #PO4-04-12
OPERA-01: A randomized, open-label, phase 3, study of palazestrant (OP-1250) vs standard-of-care treatment for ER+, HER2- advanced or metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy
Poster: 2023 San Antonio Breast Cancer Symposium. #PO3-18-09
A phase 1b/2 study of palazestrant (OP-1250), an oral complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), with palbociclib in ER-positive, HER2-negative, advanced or metastatic breast cancer patients
Poster: 2023 San Antonio Breast Cancer Symposium. #PS15-04
Results from the phase 1/2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer
Oral Presentation: European Society for Medical Oncology (ESMO) Congress 2023. #382MO
A phase 1b dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer
Poster: 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. #340a
A phase 1b/2 study of OP-1250, an oral complete estrogen receptor antagonist (CERAN) and selective er degrader (SERD) with palbociclib in patients with advanced or metastatic HR+/HER2- breast cancer
Poster: 2023 ESMO Breast Cancer Annual Congress. #202P
A phase 1b/2 dose escalation and dose expansion study of OP-1250, an oral complete estrogen receptor antagonist (CERAN)/selective estrogen receptor degrader (SERD), in combination with the CDK4/6 inhibitor palbociclib in patients with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (OP-1250-002; NCT05266105)
Poster: 2022 San Antonio Breast Cancer Symposium. #P3-07-15
Preliminary phase 1/2 results from OP-1250-001, a study of OP-1250, an oral CERAN/SERD, in patients with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)
Poster: 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2022 #101/PB091
Precision run-on sequencing (PRO-Seq) analysis of a treatment time course in ER+ breast cancer cell lines profiles the transcriptional changes underlying response to complete estrogen receptor antagonist (CERAN) OP-1250
Poster: American Association for Cancer Research Annual Meeting 2022
Preliminary data from a phase 1/2, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in patients with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer
Poster: 2021 San Antonio Breast Cancer Symposium. #P1-17-12
The complete estrogen receptor antagonist OP-1250 can combine with HER2 inhibition to inhibit estrogen receptor-driven cellular proliferation and shrink xenograft tumors in ER+/HER2+ breast cancer models
Poster: 2021 San Antonio Breast Cancer Symposium. #P5-08-07
A phase 1/2 dose escalation and expansion study of OP-1250 in adults with advanced and/or metastatic hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer
Poster: 2021 AACR-NCI-EORTC Virtual International Conference
The complete estrogen receptor antagonist (CERAN) OP-1250 shrinks ER+ breast cancer tumors expressing the ESR1-Y537S mutant estrogen receptor in an intracranial xenograft model of brain metastases
Late-breaking poster: American Association for Cancer Research Annual Meeting 2021 [Virtual]. #LB-122
A phase I/II open-label, first-in-human, multicenter, dose escalation and dose expansion study of OP-1250 monotherapy in adult subjects with locally advanced, recurrent, and metastatic hormone receptor (HR)-positive, HER2-negative breast cancer (NCT04505826)
Poster: 2020 San Antonio Breast Cancer Symposium [Virtual]. #OT-09-10
OP-1250, a complete estrogen receptor antagonist (CERAN) that penetrates the brain and prevents lethality from intracranial xenograft tumors expressing mutant ESR1
Hodges-Gallagher L, Sun R, Myles DC, et al. | Poster: American Association for Cancer Research Annual Meeting 2020 [Virtual]. #4376
“[The] findings inform future design efforts, providing a framework for structure based design for breast cancer drugs with superior antagonist and pharmacological properties."